术前帕唑帕尼改善高水平 IVC 肿瘤血栓形成的肾细胞癌手术结果。
Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis.
机构信息
Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
出版信息
In Vivo. 2019 Nov-Dec;33(6):2013-2019. doi: 10.21873/invivo.11698.
Abstract
UNLABELLED
Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis.
MATERIALS AND METHODS
We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital.
RESULTS
Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%).
CONCLUSION
Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis.
摘要
背景/目的：我们评估了在高级肾细胞癌伴下腔静脉肿瘤血栓患者中，行肾切除术和血栓切除术联合与不联合术前帕唑帕尼治疗的手术结果。
材料和方法
我们比较了在神户大学医院接受手术治疗的 19 例高级肾细胞癌伴高水平下腔静脉肿瘤血栓患者中，行术前帕唑帕尼治疗与单纯手术治疗的患者的手术结果。
结果
与单纯手术组相比，术前组的平均手术时间分别为 497 分钟和 627 分钟（p=0.08）；平均出血量分别为 1928 毫升和 7393 毫升（p<0.05）；平均术后住院时间分别为 15.3 天和 21.6 天（p=0.05）；且围手术期并发症发生率较低（术前组：33%比手术组：50%）。
结论
术前使用帕唑帕尼治疗可降低高级肾细胞癌伴高水平下腔静脉肿瘤血栓的手术难度，改善手术结果。
相似文献
1
Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis.术前帕唑帕尼改善高水平 IVC 肿瘤血栓形成的肾细胞癌手术结果。
In Vivo. 2019 Nov-Dec;33(6):2013-2019. doi: 10.21873/invivo.11698.
2
Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study.术前使用帕唑帕尼治疗伴有下腔静脉血栓的肾细胞癌：一项单机构研究。
Anticancer Drugs. 2018 Jul;29(6):565-571. doi: 10.1097/CAD.0000000000000627.
3
Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava.术前阿昔替尼治疗可增加肾癌合并瘤栓延伸至下腔静脉的肿瘤栓内纤维反应。
Int J Clin Oncol. 2018 Feb;23(1):134-141. doi: 10.1007/s10147-017-1169-z. Epub 2017 Jul 27.
4
Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.细胞减灭性肾切除术治疗下腔静脉肿瘤栓转移性肾细胞癌患者的肿瘤学结果。
Int J Clin Oncol. 2018 Jun;23(3):553-558. doi: 10.1007/s10147-017-1232-9. Epub 2018 Jan 13.
5
En bloc laparoscopic radical nephrectomy with inferior vena cava thrombectomy: A single-institution experience.整块腹腔镜下根治性肾切除术联合下腔静脉取栓术：单中心经验。
Int J Urol. 2019 Mar;26(3):363-368. doi: 10.1111/iju.13873. Epub 2018 Dec 3.
6
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.手术对接受 TKI 治疗的伴有 IVC 血栓的转移性肾细胞癌预后的影响。
J Surg Oncol. 2014 Aug;110(2):145-50. doi: 10.1002/jso.23612. Epub 2014 Apr 3.
7
Laparoscopic Radical Nephrectomy and Inferior Vena Cava Thrombectomy in the Treatment of Renal Cell Carcinoma.腹腔镜根治性肾切除术和下腔静脉取栓术治疗肾细胞癌。
Eur Urol. 2015 Jul;68(1):115-22. doi: 10.1016/j.eururo.2014.12.011. Epub 2014 Dec 19.
8
Robot-assisted Level II-III Inferior Vena Cava Tumor Thrombectomy: Step-by-Step Technique and 1-Year Outcomes.机器人辅助下腔静脉II-III级肿瘤血栓切除术：分步技术及1年随访结果
Eur Urol. 2017 Aug;72(2):267-274. doi: 10.1016/j.eururo.2016.08.066. Epub 2016 Sep 20.
9
Initial Series of Robotic Segmental Inferior Vena Cava Resection in Left Renal Cell Carcinoma With Caval Tumor Thrombus.机器人辅助左肾癌合并下腔静脉瘤栓节段性切除术的初步系列报道。
Urology. 2020 Aug;142:125-132. doi: 10.1016/j.urology.2020.03.053. Epub 2020 Apr 24.
10
[Outcome of Resection of Inferior Vena Cava Superior to the Renal Vein in Renal Cell Carcinoma with Vena Caval Tumor Thrombus].[肾细胞癌伴腔静脉瘤栓患者肾静脉上方下腔静脉切除术的结果]
Hinyokika Kiyo. 2016 Jun;62(6):287-94.
引用本文的文献
1
Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study.替雷利珠单抗联合阿昔替尼新辅助治疗伴下腔静脉瘤栓的非转移性肾细胞癌的疗效和安全性：一项回顾性研究
Sci Rep. 2025 Jan 17;15(1):2248. doi: 10.1038/s41598-025-86712-6.
2
Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.对比分析双重免疫检查点抑制剂联合治疗与免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗伴下腔静脉瘤栓的肾细胞癌。
Int J Clin Oncol. 2024 Oct;29(10):1538-1547. doi: 10.1007/s10147-024-02598-w. Epub 2024 Aug 7.
3
Effects of neoadjuvant VEGF‑TKI treatment on surgery for renal cell carcinoma: A systematic review and meta‑analysis.新辅助血管内皮生长因子酪氨酸激酶抑制剂（VEGF-TKI）治疗对肾细胞癌手术的影响：一项系统评价和荟萃分析
Oncol Lett. 2024 Feb 19;27(4):162. doi: 10.3892/ol.2024.14295. eCollection 2024 Apr.
4
The Role of Anticoagulation in Tumor Thrombus Associated with Renal Cell Carcinoma: A Literature Review.抗凝在肾细胞癌相关肿瘤血栓形成中的作用：文献综述
Cancers (Basel). 2023 Nov 13;15(22):5382. doi: 10.3390/cancers15225382.
5
Optimal Prognostic Factors for Metastatic and Inoperable Sarcomas Treated With Pazopanib, Eribulin, and Trabectedin.帕唑帕尼、艾立布林和曲贝替定治疗转移性和不可手术肉瘤的最佳预后因素。
In Vivo. 2023 Nov-Dec;37(6):2634-2641. doi: 10.21873/invivo.13371.
6
The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma.细胞减灭性肾切除术和全身治疗在转移性肾细胞癌患者肿瘤血栓管理中的作用。
Br J Cancer. 2023 May;128(10):1888-1896. doi: 10.1038/s41416-023-02166-5. Epub 2023 Mar 1.
7
Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.免疫检查点抑制剂联合治疗合并下腔静脉癌栓的肾细胞癌。
In Vivo. 2022 Mar-Apr;36(2):1030-1034. doi: 10.21873/invivo.12798.
8
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.晚期或转移性软组织肉瘤的分子靶向治疗。
Cancer Control. 2021 Jan-Dec;28:10732748211038424. doi: 10.1177/10732748211038424.
9
Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report.非转移性肾细胞癌中的IV级肿瘤血栓？不，谢谢。II级更好。从一例病例报告中吸取的教训。
Urol Case Rep. 2021 Mar 25;37:101660. doi: 10.1016/j.eucr.2021.101660. eCollection 2021 Jul.
本文引用的文献
1
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.舒尼替尼单药治疗或肾细胞癌转移患者肾切除术后的治疗。
N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.
2
Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort.早期肿瘤缩小与转移性肾细胞癌患者的总生存改善独立相关：使用 COMPARZ 队列的验证研究。
World J Urol. 2018 Sep;36(9):1423-1429. doi: 10.1007/s00345-018-2297-4. Epub 2018 Apr 13.
3
Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study.术前使用帕唑帕尼治疗伴有下腔静脉血栓的肾细胞癌：一项单机构研究。
Anticancer Drugs. 2018 Jul;29(6):565-571. doi: 10.1097/CAD.0000000000000627.
4
Neoadjuvant therapy for localized and locally advanced renal cell carcinoma.局限性及局部进展性肾细胞癌的新辅助治疗
Urol Oncol. 2018 Jan;36(1):31-37. doi: 10.1016/j.urolonc.2017.07.015. Epub 2017 Aug 10.
5
Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava.术前阿昔替尼治疗可增加肾癌合并瘤栓延伸至下腔静脉的肿瘤栓内纤维反应。
Int J Clin Oncol. 2018 Feb;23(1):134-141. doi: 10.1007/s10147-017-1169-z. Epub 2017 Jul 27.
6
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.在非转移性肾细胞癌患者中，新辅助索拉非尼治疗后肿瘤有效缩小但瘤内异质性增加。
Langenbecks Arch Surg. 2017 Jun;402(4):637-644. doi: 10.1007/s00423-016-1543-8. Epub 2016 Dec 23.
7
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
8
Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.阿昔替尼用于局部晚期非转移性透明细胞肾细胞癌患者的新辅助治疗2期试验。
Eur Urol. 2014 Nov;66(5):874-80. doi: 10.1016/j.eururo.2014.01.035. Epub 2014 Feb 7.
9
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
10
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?接受肾切除术和下腔静脉血栓切除术患者的新辅助靶向分子疗法：有用吗？
World J Urol. 2014 Feb;32(1):109-14. doi: 10.1007/s00345-013-1088-1. Epub 2013 Apr 27.
Zotero 插件